| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 21.606.348 | 26.572.759 | 26.436.353 | 23.472.858 | 26.261.313 | 45.763.568 | 52.013.092 | 60.260.056 | 66.251.553 | 78.588.037 |
| Total Income - EUR | 21.658.201 | 26.586.497 | 26.643.410 | 23.512.516 | 26.280.148 | 45.771.573 | 52.017.215 | 60.298.442 | 66.761.879 | 79.293.573 |
| Total Expenses - EUR | 20.820.910 | 24.833.869 | 27.618.412 | 22.242.297 | 25.386.506 | 44.484.551 | 49.146.014 | 57.129.033 | 68.247.827 | 74.205.703 |
| Gross Profit/Loss - EUR | 837.291 | 1.752.628 | -975.002 | 1.270.219 | 893.642 | 1.287.022 | 2.871.201 | 3.169.409 | -1.485.948 | 5.087.869 |
| Net Profit/Loss - EUR | 896.995 | 1.752.628 | -1.101.445 | 1.167.580 | 750.369 | 1.137.616 | 2.622.284 | 2.486.807 | -1.506.749 | 4.529.027 |
| Employees | 18 | 18 | 20 | 23 | 25 | 40 | 44 | 47 | 46 | 41 |
Check the financial reports for the company - Takeda Pharmaceuticals Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 31.491 | 34.796 | 113.112 | 104.262 | 291.580 | 716.524 | 575.757 | 389.614 | 237.087 | 78.749 |
| Current Assets | 17.066.194 | 20.550.424 | 18.596.441 | 16.358.366 | 24.271.439 | 37.490.826 | 36.669.373 | 46.140.023 | 45.730.551 | 65.235.773 |
| Inventories | 2.390.939 | 3.929.083 | 4.896.575 | 3.645.485 | 3.558.164 | 11.885.711 | 6.761.410 | 8.331.510 | 9.983.794 | 16.417.565 |
| Receivables | 13.310.587 | 12.159.550 | 10.400.634 | 11.002.098 | 13.923.161 | 22.519.230 | 25.914.823 | 34.290.759 | 34.413.949 | 41.923.637 |
| Cash | 1.364.668 | 4.461.792 | 3.299.232 | 1.710.783 | 6.790.114 | 3.085.885 | 3.993.140 | 3.517.754 | 1.332.808 | 6.894.571 |
| Shareholders Funds | 1.213.545 | 2.953.797 | 1.802.369 | 2.936.872 | 3.630.366 | 5.706.135 | 18.309.424 | 20.790.561 | 19.220.766 | 23.628.178 |
| Social Capital | 787 | 779 | 766 | 752 | 738 | 897 | 10.108.422 | 10.139.783 | 10.109.035 | 10.052.538 |
| Debts | 15.902.175 | 17.679.370 | 16.945.084 | 13.547.860 | 20.945.278 | 32.545.887 | 18.968.746 | 25.799.022 | 26.804.414 | 41.755.679 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Takeda Pharmaceuticals Srl